Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
This study has been terminated.
Study NCT00040651 Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First Received: July 5, 2002 Last Updated: December 19, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Scleroderma
Systemic Sclerosis
Additional conditions recognized in this trial
Scleroderma, Diffuse
Scleroderma, Systemic
Sclerosis
More general conditions related to this trial
Connective Tissue Diseases
Pathologic Processes
Skin Diseases
Interventions listed in this trial
Fludarabine
Cyclophosphamide
Thymoglobulin
Leukapheresis
Self bone marrow transplant
Additional drug interventions recognized in this trial
Fludarabine monophosphate
More general drug interventions related to this trial
Alkylating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
University of Pittsburgh
Amgen
Genzyme
Back to top of Main Content
